US20020001640A1 - Method for improving bone modeling and chondrocyte functioning in growing canines - Google Patents
Method for improving bone modeling and chondrocyte functioning in growing canines Download PDFInfo
- Publication number
- US20020001640A1 US20020001640A1 US09/785,901 US78590101A US2002001640A1 US 20020001640 A1 US20020001640 A1 US 20020001640A1 US 78590101 A US78590101 A US 78590101A US 2002001640 A1 US2002001640 A1 US 2002001640A1
- Authority
- US
- United States
- Prior art keywords
- fatty acids
- pet food
- food composition
- bone
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 29
- 241000282465 Canis Species 0.000 title claims abstract description 28
- 210000001612 chondrocyte Anatomy 0.000 title claims abstract description 13
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 50
- 235000013305 food Nutrition 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims abstract description 35
- 230000008569 process Effects 0.000 claims abstract description 26
- 239000000835 fiber Substances 0.000 claims abstract description 14
- 235000019197 fats Nutrition 0.000 claims abstract description 11
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 24
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 18
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 17
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 17
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 17
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 16
- 229930195729 fatty acid Natural products 0.000 claims description 16
- 239000000194 fatty acid Substances 0.000 claims description 16
- 150000004665 fatty acids Chemical class 0.000 claims description 16
- 235000013325 dietary fiber Nutrition 0.000 claims description 13
- 239000005416 organic matter Substances 0.000 claims description 9
- 230000000153 supplemental effect Effects 0.000 claims description 6
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 5
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 5
- 230000008034 disappearance Effects 0.000 claims description 5
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 5
- 230000002550 fecal effect Effects 0.000 claims description 4
- 235000019750 Crude protein Nutrition 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 abstract description 44
- 230000000378 dietary effect Effects 0.000 abstract description 11
- 230000011164 ossification Effects 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 230000002222 downregulating effect Effects 0.000 abstract description 5
- 230000003868 tissue accumulation Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 235000014633 carbohydrates Nutrition 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 37
- 230000037213 diet Effects 0.000 description 33
- 229940090949 docosahexaenoic acid Drugs 0.000 description 18
- 238000011282 treatment Methods 0.000 description 16
- 235000019485 Safflower oil Nutrition 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 239000003813 safflower oil Substances 0.000 description 12
- 235000005713 safflower oil Nutrition 0.000 description 12
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- 210000000845 cartilage Anatomy 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 241000273930 Brevoortia tyrannus Species 0.000 description 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000004097 bone metabolism Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000004067 Osteocalcin Human genes 0.000 description 4
- 108090000573 Osteocalcin Proteins 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- 150000004666 short chain fatty acids Chemical class 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 210000002303 tibia Anatomy 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 230000010072 bone remodeling Effects 0.000 description 3
- 235000020940 control diet Nutrition 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000014461 bone development Effects 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- -1 eicosanoid prostaglandins Chemical class 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001541238 Vachellia tortilis subsp. raddiana Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical class CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- CBOMORHDRONZRN-QLOYDKTKSA-N prostaglandin E3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CBOMORHDRONZRN-QLOYDKTKSA-N 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/805—Pet food for dog, cat, bird, or fish
Abstract
Description
- The present invention relates to a process of administering to growing canines a pet food composition comprising appropriate amounts and ratios of n-6/n-3 fatty acids to enhance bone modeling and chondrocyte functioning in those animals.
- It is known from Canadian Patent No. 2,145,716 that dietary n-6 and n-3 fatty acids (also known as omega-6 and omega-3 fatty acids) and the ratio in which they are present in the canine diet has an effect on the skin and coat health of the animal. Studies have demonstrated that the incorporation of optimal proportions of n-6 and n-3 fatty acids into the diet has a beneficial effect on canines suffering from certain inflammatory skin conditions.
- Long bone growth and bone modeling are regulated by complex interactions between a puppy's genetic potential, environmental influences, and nutrition. These interactions produce a bone architecture that balances functionally appropriate morphology with the skeleton's role in calcium and phosphorous homeostasis. Long bones of the dog increase in length and diameter by a process called modeling. Bone modeling represents an adaptive process of generalized and continuous growth and reshaping of bone governed by the activities of osteoblasts and osteoclasts until the adult bone structure is attained. Bone modeling is distinct from bone remodeling which describes the process of bone resorption and formation that maintains skeletal mass in the adult dog.
- There are numerous cell-derived growth regulatory factors present within skeletal tissues such as prostaglandins, cytokines, and growth factors which affect skeletal metabolism. Prostaglandins are believed to play a major role in bone metabolism, but also have been implicated in joint diseases. Some of the skeletal abnormalities and conditions in canines are the consequence of abnormal bone remodeling and metabolism, or in the case of arthritis, an inflammatory process.
- Growth cartilage in long bones contains chondrocytes which initiate bone mineralization through matrix vesicles which have been described as lipid-enclosed microenvironments containing acidic phospholipids that exhibit a high affinity for binding calcium ions. Polyunsaturated fatty acids (PUFA) are believed to play an important role in bone mineralization and growth because it is believed that phospholipids as well as prostaglandins are synthesized from essential PUFA.
- Recent studies have demonstrated that dietary n-6/n-3 fatty acids ratios are reflected in the fatty acid profile in the bones and growth cartilage of growing chicks and in the bones of rats. In these studies, chicks provided with soybean oil in their diet had greater values for ex vivo PGE2 (prostaglandin E2) production in liver and bone cultures, but lower bone formation rates as compared to chicks fed menhaden oil. The level of PGE2 produced locally at the bone appears to be a critical factor in bone formation in that it is stimulatory at moderate levels and inhibitory at high levels. The mechanism by which prostaglandins regulate bone metabolism is uncertain but it has been suggested that it may be mediated through the IGF system and(or) cytokines.
- Accordingly, the need remains in the art for a diet which promotes bone/cartilage biology and health in the growing canine, which diet includes appropriate amounts of dietary n-6 and n-3 fatty acids.
- The present invention meets that need by providing a process of administering to a growing canine a pet food composition comprising an appropriate amount and ratio of dietary n-6 and n-3 fatty acids to provide improved bone modeling and chondrocyte functioning. In accordance with one aspect of the present invention, a process is provided for improving bone modeling and chondrocyte functioning in a growing canine comprising the step of feeding the growing canine a pet food composition comprising n-6 and n-3 fatty acids in an amount and ratio effective to improve bone modeling and chondrocyte functioning. The ratio of n-6 fatty acids to n-3 fatty acids is preferably from about 20:1 to about 1:1, more preferably, from about 10:1 to about 5:1, and most preferably, from about 8:1 to about 5:1. It is preferred that at least about 22 wt% of the total fatty acids in the pet food composition are n-6 fatty acids. It is also preferred that at least about 3 wt% of the total fatty acids in the pet food composition are n-3 fatty acids.
- Preferably, the pet food composition comprises from about 0.88 to about 6.6% by weight n-6 fatty acids and from about 0.16 to about 1.2% by weight n-3 fatty acids, on a dry matter basis. Thus, both the amount of n-3 fatty acids in the pet food composition, as well as the ratio of n-6 to n-3 fatty acids, are important. In a preferred embodiment, the n-3 fatty acids provided in the pet food composition comprise eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
- Preferably, the pet food composition comprises from about 20 to about 40 wt% crude protein, from about 4 to about 30 wt% fat, from about 2 to about 20 wt% total dietary fiber, and a source of carbohydrates. No specific ratios or percentages of these nutrients are required.
- The pet food composition may further comprise from about 1 to about 11 weight percent of supplemental total dietary fiber of fermentable fibers which have an organic matter disappearance of 15 to 60 weight percent when fermented by fecal bacteria for a 24 hour period.
- Accordingly, it is a feature of the present invention to provide a process for improving bone modeling and chondrocyte functioning in a growing canine. This, and other features and advantages of the present invention will become apparent from the following detailed description and the appended claims.
- The present invention utilizes a pet food composition which aids in promoting bone development in growing canines by providing appropriate amounts of n-6 and n-3 fatty acids, and in proper ratios, to stimulate chondrocyte functioning and bone development. The pet food composition may be provided in any suitable form as long as it contains the preferred concentrations of n-3 and n-6 fatty acids.
- In adult canines, abnormal bone remodeling and metabolism can cause skeletal pathologies. Feeding the pet food composition of the present invention to growing canines early in life may delay or lessen the onset and severity of some of these pathologies. Therefore, growing canines will especially benefit from being fed the pet food composition of the present invention.
- It has been discovered that by adjusting the ratio of n-6 to n-3 fatty acids in the pet food composition, the level of certain pro-inflammatory eicosanoid prostaglandins (PGE2) are depressed. In accordance with the preferred embodiment of the present invention, the pet food composition comprises a ratio of n-6 fatty acids to n-3 fatty acids that is from about 20:1 to about 1:1. More preferably, this weight ratio is from about 10:1 to about 5:1. Most preferably, this weight ratio is from about 8:1 to about 5:1. Preferably, at least about 22 wt% of the total fatty acids in the pet food composition are n-6 fatty acids. It is also preferred that at least about 3 wt% of the total fatty acids in the pet food composition are n-3 fatty acids. The pet food composition also preferably comprises from about 0.88 to about 6.6% by weight n-6 fatty acids and from about 0.16 to about 1.2% by weight n-3 fatty acids, on a dry matter basis.
- Synthesis and tissue accumulation of down regulating elements of inflammation such as the n-3 fatty acids eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively) are also promoted by adjusting the ratio of n-6 to n-3 fatty acids in the pet food composition of the present invention, which stimulates bone formation and optimizes bone modeling. Further, by providing specific sources of n-3 fatty acids to the pet food composition, tissue accumulation of anti-inflammatory PGE3 series prostaglandins is promoted as well. Preferably, the n-3 fatty acids of the pet food composition of the present invention comprise EPA and DHA.
- The pet food composition can be any suitable pet food formula that also provides adequate nutrition for the animal. For example, a typical canine diet for use in the present invention may contain from about 20 to about 40 wt% crude protein, from about 4 to about 30 wt% fat, and from about 2 to about 20 wt% total dietary fiber, along with a source of carbohydrates. Suitable sources of protein for use in the pet food composition include, but are not limited to, chicken and chicken-by-products, chicken digest, brewers dried yeast, and DL-methionine. Suitable sources of fat include chicken fat (preserved with mixed tocopherols), fish oil, and flax.
- The pet food composition of the present invention may also optionally contain a source of fermentable fibers that display certain organic matter disappearance percentages. The fermentable fibers that may be used have an organic matter disappearance (OMD) of from about 15 to 60 percent when fermented by fecal bacteria in vitro for a 24 hour period. That is, from about 15 to 60 percent of the total organic matter originally present is fermented and converted by the fecal bacteria. The organic matter disappearance of the fibers is preferably 20 to 50 percent, and most preferably is 30 to 40 percent.
- Thus, in vitro OMD percentage may be calculated as follows:
- {1−[(OM residue—OM blank)/OM initial]}x100,
- where OM residue is the organic matter recovered after 24 hours of fermentation, OM blank is the organic matter recovered in corresponding blank tubes (i.e., tubes containing medium and diluted feces, but no substrate), and OM initial is that organic matter placed into the tube priorto fermentation. Additional details of the procedure are found in Sunvold et al., J. Anim. Sci. 1995, vol. 73:1099-1109.
- The fermentable fibers may be any fiber source that intestinal bacteria present in the animal can ferment to produce significant quantities of short chain fatty acids (SCFAs). “Significant quantities” of SCFAs, for purposes of this invention, are amounts over 0.5 mmol of total SCFAs/gram of substrate in a 24-hour period. Preferred fibers include beet pulp, gum arabic (including gum talha), psyllium, rice bran, carob bean gum, citrus pulp, pectin, fructooligosaccharids and inulin, mannanoligosaccharides and mixtures of these fibers.
- The fermentable fibers are used in the pet food composition in amounts from 1 to 11 weight percent of supplemental total dietary fiber, preferably from 2 to 9 weight percent, more preferably from 3 to 7 weight percent, and most preferably from 4 to 7 weight percent.
- A definition of “supplemental total dietary fiber” first requires an explanation of “total dietary fiber”. “Total dietary fiber” is defined as the residue of plant food which is resistant to hydrolysis by animal digestive enzymes. The main components of total dietary fiber are cellulose, hemicellulose, pectin, lignin, and gums (as opposed to “crude fiber”, which only contains some forms of cellulose and lignin). “Supplemental total dietary fiber” is that dietary fiber which is added to a food product above and beyond any dietary fiber naturally present in other components of the food product. Also, a “fiber source” is considered such when it consists predominantly of fiber.
- In order that the invention may be more readily understood, reference is made to the following examples, which are intended to be illustrative of the invention, but are not intended to be limiting in scope.
- A canine study evaluated the dietary n-3 and n-6 fatty acid effects on the fatty acid composition of bone compartments in coonhounds. A total of 32 eight-week-old purpose-bred puppies were allocated to four dietary treatments differing only in fatty acid source. Treatment diets were isonitrogenous, isocaloric and formulated to provide n-6/n-3 ratios ranging from 5:1 to 50:1. The canine growth diet was formulated to contain different ratios of n-6/n-3 fatty acids, 5:1, 5:1, 50:1, and 25:1, using the following lipid sources: docosahexaenoic acid (DHA), menhaden oil (MEN), safflower oil (SAF) and poultry fat (control). Treatments 3 and 4 evaluated the effect of n-3 fatty acid source (Treatment 3 =DHA; Treatment 4=DNA). Puppies were fed the treatment diets for a total of 18 weeks, 2 of weeks conditioning followed by 16 weeks of treatment. The results of the study are reported below.
Treatment No. Fat Source n-6/n-3 Ratio* 1 Poultry Fat 25:1 2 Safflower Oil 50:1 3 Menhaden Oil 5:1 4 DHA Source 5:1 - The response criteria evaluated was as follows:
Days on Test Response Criteria 0 Serum TNF, IL-1 and IL-6. 4 Serum TNF, IL-1 and IL-6. 8 Serum TNF, IL-1, IL-6, lipids, osteocalcin, alkaline phosphatase and IGF-1. 12 Serum TNF, IL-1 and IL-6. 16 Serum TNF, IL-1, IL-6, lipids, osteocalcin, alkaline phosphatase and IGF-1. Bone (Ileum) formation rate, histomorphometry, fatty acids. - MEN and DNA diets elicited significant elevations in 22:6n-3 (DHA) relative to the control diet in neutral and polar lipids of tibia cortical and trabecular bone, marrow and periosteum. The MEN diet resulted in a significantly higher concentration of 20:5n-3 (EPA) in both lipid fractions of all tissues. The concentration of 18:2n-6 (linoleic acid) was significantly higher in both lipid fractions of all tissues except marrow polar lipids of those given the SAF diet. The MEN and DHA diets depressed 18:2n-6 in the polar lipid fractions of trabecular bone and marrow. In the MEN and DHA enriched diets, arachidonic acid (AA; 20:4n-6) concentration was significantly depressed and 22:6n-3 elevated in the neutral lipid fraction of periosteum. Both the MEN and DHA diets reduced 18:2n-6 and increased n-3 fatty acids in ligaments compared to the values in dogs given control and SAF-containing diets.
- These data showed that both EPA and DHA were enriched in bone compartments, and that DHA accumulated to a greater extent in cortical bone polar lipids than EPA. Based on ex vivo PGE2 production in iliac crest tissue, the MEN diet tended to lower prostanoid formation. Moreover, the down-regulating elements of inflammation (PGE3) are stimulated by the presence of EPA. These results suggest that diets rich in n-3 fatty acids reduce pro-inflammatory eicosanoid (PGE2) synthesis and promote tissue accumulation of down-regulating elements of inflammation (EPA and DHA) in bone compartments of canines. These results also suggest that pro-inflammatory PGE2 production will be elevated by a dietary n-6/n-3 fatty acid ratio of 25:1 or greater and thereby depress bone formation, while a ratio of 5:1 will lower the level of PGE2 and thereby stimulate bone formation and optimize bone modeling in the growing canine. The specific n-3 fatty acid (20:5n-3 or 22:6n-3) in the diet may also differentially modulate effects on cartilage and bone metabolism in the growing canine.
- A study using rats was performed. The study was needed due to the nature of the data to be collected and the impracticality of collecting such data from the growing canine. Data collected included (1) harvesting of organs and tissues, (2) determination of bone formation rates (BFR) and growth cartilage morphometry as a measure of bone modeling, and (3) evaluation of mechanical properties on intact bones.
- A total of 40 weanling male Harlan Sprague-Dawley rats (21 days old) were allocated to four dietary treatments for 42 days. The control diet (Treatment 1) was AIN93G (diet as reported by Reeves et al, AIN-93 Purified Diets for Laboratory Rodents, 123 J. Nutrition 1939-51 (1993)) that contained soybean oil and an n-6/n-3 fatty acid ratio of 8:1. The other three treatment diets provided supplemental fatty acids to mirror the n-6/n-3 fatty acid ratios of the canine experiment as closely as possible. The control diet contained 70 g/kg of added fat. The otherthree treatment diets were formulated with lipids to provide the following ratios of (n-6)/(n-3) fatty acids: 8:1 (soybean oil (SBO)), 50:1 (safflower oil (SAF)), 5:1 (docosahexaenoic acid (DHA)), and 5:1 (Menhaden oil (MEN)). Treatment diets are summarized in the following table:
Treatment No. Fat Source n-6/n-3 Ratio* 1 Soybean oil 8:1 2 Safflower Oil 50:1 3 Menhaden Oil 5:1 4 DHA Source 5:1 - The response criteria evaluated was as follows:
Days on Test Response Criteria 21 Serum IGF-1, BP-3, osteocalcin and alkaline phosphatase. 42 Serum IGF-1, BP-3, osteocalcin, alkaline phosphatase and fatty acids. Bone histomorphometric measurements on growth plate cartilage and trabecular bone. Bone fatty acids, PGE2 and IGF-1. Tibia and femur mechanical properties. - The MEN and DHA diets significantly elevated the concentrations of 20:5n-3 (EPA) and 22:6n-3 (DHA) in tibia cortical bone and marrow compared to the values in those given the SAF diet. The concentration of 20:4n-6 (M) in bone compartments was unchanged by the dietary treatments. The DHA concentration in bone was lowest in rats given the SAF diet.
- These data showed that both EPA and DHAwere enriched in bone compartments, and that DHA accumulated to a greater extent in cortical bone polar lipids than EPA. Ex vivo PGE2 production in the tibia was reduced in rats given the DHA diet compared to those on the SAF diet. Serum bone specific alkaline phosphatase was elevated in rats given the MEN diet compared to values in rats given the other diets. Total trabecular number and marrow area were higher in the DHA group compared with the SBO group; however, periosteal BFR was higher in those given the SBO and SAF diets. No differences were found between the dietary treatments for endosteal bone formation rates.
- The results suggest that diets rich in n-3 fatty acids reduce pro-inflammatory eicosanoid (PGE2) synthesis and promote tissue accumulation of down-regulating elements of inflammation (EPA and DHA) in bone compartments.
- While certain representative embodiments and details have been shown for purposes of illustrating the invention, it will be apparent to those skilled in the art that various changes in the methods and apparatus disclosed herein may be made without departing from the scope of the invention, which is defined in the appended claims.
Claims (17)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/785,901 US6426100B2 (en) | 2000-02-17 | 2001-02-16 | Method for improving bone modeling and chondrocyte functioning in growing canines |
US10/173,141 US20030031753A1 (en) | 2000-02-17 | 2002-06-17 | Method for improving bone modeling and chondrocyte functioning in growing canines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18329400P | 2000-02-17 | 2000-02-17 | |
US09/785,901 US6426100B2 (en) | 2000-02-17 | 2001-02-16 | Method for improving bone modeling and chondrocyte functioning in growing canines |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/173,141 Continuation US20030031753A1 (en) | 2000-02-17 | 2002-06-17 | Method for improving bone modeling and chondrocyte functioning in growing canines |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020001640A1 true US20020001640A1 (en) | 2002-01-03 |
US6426100B2 US6426100B2 (en) | 2002-07-30 |
Family
ID=22672227
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/785,901 Expired - Lifetime US6426100B2 (en) | 2000-02-17 | 2001-02-16 | Method for improving bone modeling and chondrocyte functioning in growing canines |
US10/173,141 Abandoned US20030031753A1 (en) | 2000-02-17 | 2002-06-17 | Method for improving bone modeling and chondrocyte functioning in growing canines |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/173,141 Abandoned US20030031753A1 (en) | 2000-02-17 | 2002-06-17 | Method for improving bone modeling and chondrocyte functioning in growing canines |
Country Status (11)
Country | Link |
---|---|
US (2) | US6426100B2 (en) |
EP (1) | EP1255546B9 (en) |
JP (2) | JP2003522788A (en) |
AR (1) | AR033967A1 (en) |
AT (1) | ATE294576T1 (en) |
AU (1) | AU2001238423A1 (en) |
CA (1) | CA2400461C (en) |
DE (1) | DE60110553T2 (en) |
EG (1) | EG22407A (en) |
MX (1) | MXPA02007976A (en) |
WO (1) | WO2001060356A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050043405A1 (en) * | 2003-08-11 | 2005-02-24 | Fritsch Dale A. | Omega-3 fatty acids for osteoarthritis |
JP2008526214A (en) * | 2004-12-30 | 2008-07-24 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Methods for improving the quality of life of growing animals |
WO2008103958A1 (en) * | 2007-02-22 | 2008-08-28 | Hill's Pet Nutrition, Inc. | Compositions and methods for altering gene expression |
US20100256236A1 (en) * | 2003-08-11 | 2010-10-07 | Hill's Pet Nutrition, Inc. | Methods for decreasing cartilage damage in dogs |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030194478A1 (en) * | 2002-04-12 | 2003-10-16 | Davenport Gary Mitchell | Dietary methods for canine performance enhancement |
US8841344B2 (en) * | 2002-10-03 | 2014-09-23 | Hill's Pet Nutrition, Inc. | Method of using omega-3 fatty acids |
GB0311081D0 (en) * | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
RU2422140C2 (en) * | 2003-08-11 | 2011-06-27 | Хилл'С Пет Ньютришн, Инк. | Application of omega-3 fatty acids in treatment of osteorthritis in canids |
EP2324828A1 (en) * | 2003-08-18 | 2011-05-25 | BTG International Limited | Treatment for neurodegenerative conditions |
US7875291B1 (en) | 2003-09-05 | 2011-01-25 | Glu-Pro, Inc. | Composition for managing diabetes, obesity, and hyperlipidemia and associated methods |
US8921422B2 (en) * | 2003-10-01 | 2014-12-30 | The Iams Company | Methods and kits for enhancing ability to learn in a puppy or kitten |
US20050266051A1 (en) * | 2004-05-27 | 2005-12-01 | The Procter & Gamble Company | Pet food compositions and methods |
WO2006002976A2 (en) * | 2004-07-01 | 2006-01-12 | Nestec S.A. | Canine osteoarthritis diet formulation |
GB0425932D0 (en) * | 2004-11-25 | 2004-12-29 | Btg Int Ltd | Structured phospholipids |
US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
GB0504333D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
GB0504362D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
MX2009001422A (en) * | 2006-08-09 | 2009-02-19 | Iams Company | Methods of improving bone health and muscle health. |
US9420807B2 (en) | 2007-04-02 | 2016-08-23 | Purina Animal Nutrition Llc | Method of feeding young monogastric mammals and composition fed to young monogastric mammals |
US8529965B2 (en) | 2007-07-09 | 2013-09-10 | Hill's Pet Nutrition, Inc. | Compositions and methods for altering stool quality in an animal |
WO2009008882A1 (en) * | 2007-07-09 | 2009-01-15 | Hill's Pet Nurtition, Inc. | Compositions and methods for altering stool quality in an animal |
JP2010079993A (en) * | 2008-09-26 | 2010-04-08 | Toshiba Storage Device Corp | Storage device and method for adjusting storage device |
US8060617B2 (en) * | 2008-12-19 | 2011-11-15 | Cisco Technology, Inc. | Reserving network resources during scheduling of meeting event |
AU2010276259B2 (en) * | 2009-07-21 | 2013-04-18 | Hill's Pet Nutrition, Inc. | Companion animal nutrition system |
MX2014000419A (en) | 2011-07-15 | 2014-09-22 | Nusirt Sciences Inc | Compositions and methods for modulating metabolic pathways. |
CN108452311A (en) | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | Composition for enhancing energetic supersession and method |
JP2014138564A (en) * | 2013-01-21 | 2014-07-31 | Taiyo Yushi Kk | Pet food, and additive for pet food and method of producing the same |
US20160000737A1 (en) * | 2013-03-15 | 2016-01-07 | Nusirt Sciences, Inc. | Treatment of pets with sirtuin activators |
WO2018109670A1 (en) * | 2016-12-15 | 2018-06-21 | Nestec Sa | Compositions and methods that modulate vitamin d and bone mineral content in a companion animal |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0625057B2 (en) | 1987-12-14 | 1994-04-06 | 日本油脂株式会社 | Bone formation promoter |
US5069903A (en) | 1987-12-16 | 1991-12-03 | Stitt Paul A | Therapeutic and nutritive flax seed composition and methods employing the same |
JPH02292397A (en) * | 1989-05-02 | 1990-12-03 | Lion Corp | Edible oil or fat composition and processed food |
JPH04253908A (en) * | 1990-12-28 | 1992-09-09 | Nippon Oil & Fats Co Ltd | Therapeutic agent for osteoporosis |
GB9217780D0 (en) * | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
JPH0692847A (en) | 1992-09-11 | 1994-04-05 | Mochida Pharmaceut Co Ltd | Therapeutic agent for osteoporosis |
DE4240713C1 (en) | 1992-12-03 | 1994-01-27 | Georg Prof Dr Dietz | Calcium hydroxide and oleum pedum tauri mixture - opt. also contains barium sulphate and vaseline end can be used to promote collagen formation in healing bones |
US5616569A (en) | 1994-03-28 | 1997-04-01 | The Iams Company | Pet food product containing fermentable fibers and process for treating gastrointestinal disorders |
CA2147109A1 (en) * | 1994-04-18 | 1995-10-19 | Gregory A. Reinhart | Pet food product containing omega-6 and omega-3 fatty acids and process for reducing inflammatory skin responses |
GB9506837D0 (en) | 1995-04-03 | 1995-05-24 | Scotia Holdings Plc | Triglycerides |
JPH10127257A (en) | 1996-10-28 | 1998-05-19 | Takashi Morita | Food, drink, all kinds of liquors, miso (fermented bean paste), general soy cause food an domestic animal feed, pet food and compounded food containing docosahexaenoic acid, eicosapentaenoic acid, linolic acid, protein, calcium, vitamins and other many nutrients |
US5965175A (en) * | 1997-03-27 | 1999-10-12 | The Iams Company | Composition and method for repartitioning nitrogen and increasing colonic blood flow in dogs to promote intestinal health |
US6133323A (en) * | 1997-04-09 | 2000-10-17 | The Iams Company | Process for enhancing immune response in animals using β-carotene as a dietary supplement |
ATE225191T1 (en) | 1998-04-16 | 2002-10-15 | Georg Prof Dr Dietz | PREPARATION FOR REFORMING COLLAGEN |
-
2001
- 2001-02-14 EG EG20010137A patent/EG22407A/en active
- 2001-02-16 AR ARP010100704A patent/AR033967A1/en unknown
- 2001-02-16 JP JP2001559454A patent/JP2003522788A/en active Pending
- 2001-02-16 MX MXPA02007976A patent/MXPA02007976A/en active IP Right Grant
- 2001-02-16 WO PCT/US2001/005094 patent/WO2001060356A1/en active IP Right Grant
- 2001-02-16 AT AT01910860T patent/ATE294576T1/en not_active IP Right Cessation
- 2001-02-16 DE DE60110553T patent/DE60110553T2/en not_active Expired - Lifetime
- 2001-02-16 EP EP01910860A patent/EP1255546B9/en not_active Expired - Lifetime
- 2001-02-16 AU AU2001238423A patent/AU2001238423A1/en not_active Abandoned
- 2001-02-16 US US09/785,901 patent/US6426100B2/en not_active Expired - Lifetime
- 2001-02-16 CA CA002400461A patent/CA2400461C/en not_active Expired - Lifetime
-
2002
- 2002-06-17 US US10/173,141 patent/US20030031753A1/en not_active Abandoned
-
2011
- 2011-04-04 JP JP2011082367A patent/JP2011130774A/en active Pending
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100256236A1 (en) * | 2003-08-11 | 2010-10-07 | Hill's Pet Nutrition, Inc. | Methods for decreasing cartilage damage in dogs |
US8633247B2 (en) | 2003-08-11 | 2014-01-21 | Hill's Pet Nutrition, Inc. | Method for decreasing cartilage damage in dogs |
US8633246B2 (en) | 2003-08-11 | 2014-01-21 | Hill's Pet Nutrition, Inc. | Omega-3 fatty acids for osteoarthritis |
US8629183B2 (en) | 2003-08-11 | 2014-01-14 | Hill's Pet Nutrition, Inc. | Methods for decreasing cartilage damage in dogs |
US8629182B2 (en) | 2003-08-11 | 2014-01-14 | Hill's Pet Nutrition, Inc. | Method for decreasing cartilage damage in dogs |
US20100261793A1 (en) * | 2003-08-11 | 2010-10-14 | Hill's Pet Nutrition, Inc. | Method for decreasing cartilage damage in dogs |
US20050043405A1 (en) * | 2003-08-11 | 2005-02-24 | Fritsch Dale A. | Omega-3 fatty acids for osteoarthritis |
JP2008526214A (en) * | 2004-12-30 | 2008-07-24 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Methods for improving the quality of life of growing animals |
JP2014221071A (en) * | 2004-12-30 | 2014-11-27 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Method for enhancing quality of life of growing animal |
US20100143497A1 (en) * | 2007-02-22 | 2010-06-10 | Hill's Pet Nutrition, Inc. | Compositions and Methods For Promoting Bone Development |
US20100137404A1 (en) * | 2007-02-22 | 2010-06-03 | Hill's Pet Nutrition, Inc. | Compositions and Methods for Altering Gene Expression |
US20110059202A1 (en) * | 2007-02-22 | 2011-03-10 | Steven Curtis Zicker | Compositions and Methods For Enhancing The Development of Growing Animals |
AU2008218193B2 (en) * | 2007-02-22 | 2011-09-29 | Hill's Pet Nutrition, Inc. | Compositions and methods for promoting bone development |
US20100093859A1 (en) * | 2007-02-22 | 2010-04-15 | Hill's Pet Nutrition, Inc. | Compositions and Methods For Enhancing Neurological Development |
CN101686712A (en) * | 2007-02-22 | 2010-03-31 | 希尔氏宠物营养品公司 | Compositions and methods for enhancing the development of growing animals |
WO2008103956A1 (en) | 2007-02-22 | 2008-08-28 | Hill's Pet Nutrition, Inc. | Compositions and methods for promoting bone development |
WO2008103939A1 (en) * | 2007-02-22 | 2008-08-28 | Hill's Pet Nutrition, Inc. | Compositions and methods for enhancing the development of growing animals |
WO2008103958A1 (en) * | 2007-02-22 | 2008-08-28 | Hill's Pet Nutrition, Inc. | Compositions and methods for altering gene expression |
US9888709B2 (en) | 2007-02-22 | 2018-02-13 | Hlll's Pet Nutrition, Inc. | Compositions and methods for enhancing neurological development |
Also Published As
Publication number | Publication date |
---|---|
US6426100B2 (en) | 2002-07-30 |
AU2001238423A1 (en) | 2001-08-27 |
DE60110553D1 (en) | 2005-06-09 |
CA2400461C (en) | 2009-10-06 |
EP1255546B9 (en) | 2005-09-28 |
WO2001060356A1 (en) | 2001-08-23 |
MXPA02007976A (en) | 2003-01-28 |
EP1255546B1 (en) | 2005-05-04 |
AR033967A1 (en) | 2004-01-21 |
US20030031753A1 (en) | 2003-02-13 |
EG22407A (en) | 2003-01-29 |
WO2001060356B1 (en) | 2001-12-27 |
ATE294576T1 (en) | 2005-05-15 |
JP2003522788A (en) | 2003-07-29 |
CA2400461A1 (en) | 2001-08-23 |
JP2011130774A (en) | 2011-07-07 |
EP1255546A1 (en) | 2002-11-13 |
DE60110553T2 (en) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6426100B2 (en) | Method for improving bone modeling and chondrocyte functioning in growing canines | |
US6039952A (en) | Composition and method for improving clinical signs in animals with renal disease | |
CA2145716C (en) | Pet food product containing fermentable fibers and process for treating gastrointestinal disorders | |
EP1771091B1 (en) | Canine osteoarthritis diet formulation | |
AU725604B2 (en) | Pet food composition | |
Li et al. | Bone mineral content is positively correlated to n-3 fatty acids in the femur of growing rats | |
EP0678247A1 (en) | Pet food product containing omega-6 and omega-3 fatty acids | |
JP2007169289A (en) | Process and composition for controlling fecal hair excretion and trichobezoar formation | |
Corbee et al. | Inflammation and wound healing in cats with chronic gingivitis/stomatitis after extraction of all premolars and molars were not affected by feeding of two diets with different omega‐6/omega‐3 polyunsaturated fatty acid ratios | |
Liu et al. | Effects of long-term dietary lipids on mature bone mineral content, collagen, crosslinks, and prostaglandin E2 production in Japanese quail | |
Liu et al. | Maternal dietary lipids modify composition of bone lipids and ex vivo prostaglandin E2 production in early postnatal Japanese quail | |
US5958898A (en) | Process for altering the function and composition of gut associated lymphoid tissue in an animal | |
Kellogg | On the site of the microbiological reduction of cholesterol to coprostanol in the rat | |
Sklan | A note on production responses of lactating ewes to calcium soaps of fatty acids | |
JP2834005B2 (en) | Method for producing edible bird eggs and feed for egg collection | |
JPH0371100B2 (en) | ||
Beynen | Omega-6: 3 ratio in dog food | |
Al-Sultan | Effect of dietary fish oil on production traits and lipid composition of laying hens | |
Liu | The effects of dietary lipids on bone chemical, mechanical, and histological properties in Japanese quail (Coturnix C. Japonica) | |
Kováč et al. | Blood Plasma Fatty Acid Levels in Cattle During the Transitional Feeding Period (Winter-Summer) | |
MAERTENS | Ministry of Small Enterprises, Trade and Agriculture, Center for Agricultural Research-Ghent, Department of Animal Nutrition and Husbandry, Burg. Van Gansberghelaan, 92, 9820 MERELBEKE-Belgium | |
Coves et al. | Influence of intestinal resection and type of diet on the digestive and metabolic utilization of fats in rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IAMS COMPANY, THE, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WATKINS, BRUCE A.;LEPINE, ALLAN J.;HAYEK, MICHAEL G.;AND OTHERS;REEL/FRAME:011782/0535;SIGNING DATES FROM 20010212 TO 20010214 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: MARS, INCORPORATED, VIRGINIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE IAMS COMPANY;REEL/FRAME:037197/0153 Effective date: 20151027 |